Melatonin Synergizes BRAF-targeting Agent Vemurafenib in Melanoma Treatment by Inhibiting iNOS/hTERT Signaling and Cancer-Stem Cell Traits

Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/s13046-019-1036-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Dermatology Research and Practice
Dermatology
2012English

Targeting the BRAF Signaling Pathway in CD133pos Cancer Stem Cells of Anaplastic Thyroid Carcinoma

Asian Pacific Journal of Cancer Prevention
2019English

MicroRNA-491-5p Suppresses Cervical Cancer Cell Growth by Targeting hTERT

Oncology Reports
MedicineCancer ResearchOncology
2015English

Synergistic Effects of Vemurafenib and Fingolimod (FTY720) in Vemurafenib‑resistant Melanoma Cell Lines

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Vemurafenib in the Treatment of Brain Metastases From Melanoma

Onkologiya. Zhurnal imeni P.A.Gertsena
2014English

Inhibition of YAP Function Overcomes BRAF Inhibitor Resistance in Melanoma Cancer Stem Cells

Oncotarget
Oncology
2017English

Targeting TAZ-driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Estimation of the Cancer Risk Induced by Therapies Targeting Stem Cell Replication and Treatment Recommendations

Scientific Reports
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy